Top Healthcare and Biotech Focused Hedge Funds see assets jump by 35%

November 5th, 2013
| More
The Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $58 billion in U.S. equity assets, up from $43 billion at the end of Q1. The top 50 hedge funds allocate $37.2 billion, or 64% of their total equity assets, to Healthcare, Pharma & Biotech stocks.

The Top Healthcare, Pharma & Biotech Hedge Fund List is once again led by Larry Robbins’ Glenview Capital Management and Samuel Isaly‘s OrbiMed Advisors. While Isaly’s OrbiMed Advisors is purely a healthcare focused investor, Robbins’ Glenview Capital is a global long/short equity investor that opportunistically makes big sector bets. New York based Baker Bros. Advisors LLC is the third largest hedge fund on the list, holding on to the third spot for the second consecutive quarter.

Some other notable hedge funds near the top of the hedge fund list include #11 Palo Alto Investors and #12 Brave Warrior Advisors. William Edwards’ growth focused Palo Alto Investors reported U.S. equity assets of $847 million, allocating 100% of its assets to Healthcare, Pharma & Biotech equities. The California-based firm focuses on healthcare and biotech stocks, typically concentrating its portfolio on 30 to 40 top stocks.

Glenn Greenberg’s Brave Warrior Advisors reported U.S. equity assets of $2.2 billion, dedicating 39% of its assets to Healthcare, Pharma & Biotech equities. Greenberg co-founded Chieftain Capital Management back in 1984 along with former partner John Shapiro. In 2009, the two founders split ways, with Shapiro retaining the Chieftain Capital Management for his hedge fund spin-off.

Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies, as of 6/30/2013. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below:
Brave Warrior Advisors
Chieftain Capital Management
Glenview Capital Management
OrbiMed Advisors
Palo Alto Investors
Related People: Bryan R. Lawrence; Dr. Anthony Yun; Glenn Greenberg; Glenn Greenberg*; John Shapiro*; John Shapiro: Tom Stern; Joshua Slocum; Larry Robbins; Mary Mulholland; Samuel Isaly; Tom Stern*; William Edwards
Related Entities: Brave Warrior Advisors*; Caduceus Asia Partners LP; Caduceus Capital LP; Chieftain Capital Management*; Chieftain Hawkeye Partners LP; Chieftain Hawkeye Partners LP; Eaton Vance Worldwide Health Sciences; Finsbury Worldwide Pharmaceutical; GCM Little Arbor Institutional Partners; GCM Little Arbor Master; GCM Little Arbor Partners; Glenview Capital Master; Glenview Capital Partners; Glenview Institutional Partners; OrbiMed Associates; OrbiMed Capital; Palo Alto Global Energy Fund LP; Palo Alto Healthcare Fund LP; Palo Alto Small Cap Fund LP; Palo Alto Technology Fund
Related Article Tags: Investment Management, Fund Manager and General Financial News


More Recent Headlines

Small Hedge Funds Scramble for Survival from the Scraps of Large Hedge Funds

Top Emerging Hedge Fund Managers Dip Slightly; Corvex Management sees significant growth; PDT falls

Top 50 California Hedge Funds up 2%; ValueAct Capital and SPO Advisory Hold on to Top Spots

Top New York Metro Area Hedge Funds see assets jump by nearly 25% YTD

China Taps Winton Capital, Oak Tree, Citadel, Man Group, Canyon & Och-Ziff for Foreign Investment Quota

Top Mid-Sized Hedge Funds oversee $67 Billion, Emerging Managers Account for more than 20% of Top Funds

Diamond Capital founder Richard Schimel makes a comeback with Sterling Ridge Capital Management launch

Top Hedge Funds Eclipse $730 billion Mark, Assets up 23% Year-to-Date

Goldman Sachs Investment Partners Set to Launch Asia-Focused Oryza Capital Hedge Fund

AIFMD for Americans: What US & Non-EU Managers need to do to Comply